UBS AM’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

UBS AM’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-330,528	Closed	-$6.66M	–	2932
2021 Q3	$6.66M	Sell	330,528 -10,203	-3%	-$282K	﹤0.01%	1246
2021 Q2	$12.7M	Sell	340,731 -1,809	-0.5%	-$55.4K	0.01%	1038
2021 Q1	$8.76M	Buy	342,540 +6,558	+2%	+$168K	﹤0.01%	1127
2020 Q4	$7.4M	Sell	335,982 -17,976	-5%	-$396K	﹤0.01%	1154
2020 Q3	$6.37M	Buy	353,958 +2,822	+0.8%	+$58.4K	﹤0.01%	1073
2020 Q2	$8.92M	Buy	351,136 +23,494	+7%	+$506K	0.01%	935
2020 Q1	$6.02M	Buy	327,642 +269,359	+462%	+$5.24M	﹤0.01%	994
2019 Q4	$1.28M	Buy	58,283 +8,372	+17%	+$168K	﹤0.01%	1791
2019 Q3	$717K	Buy	49,911 +15,522	+45%	+$222K	﹤0.01%	2112
2019 Q2	$542K	Buy	34,389 +18,287	+114%	+$249K	﹤0.01%	2177
2019 Q1	$236K	Hold	16,102	–	–	﹤0.01%	2403
2018 Q4	$172K	Buy	+16,102	New	+$212K	﹤0.01%	2431

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

UBS AM's DRNA Position: Q4 2021 in Review

UBS AM sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 330,528 shares — an estimated $6.66M sold.

UBS AM first reported a position in DRNA in Q4 2018 and held it in 12 quarters. The position peaked at $12.7M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

UBS AM reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
UBS AM sold 330,528 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $6.66M.
UBS AM first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2018 and held it in 12 quarters.
UBS AM's Dicerna Pharmaceuticals, Inc. position peaked at $12.7M in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on UBS AM's 13F filing for Q4 2021, filed 14 Feb 2022.